ReviewPharmaceuticals (Basel, Switzerland)2020
Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications.
Review in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Risk of COVID-19 infection and the associated hospitalization, ICU admission and mortality in opioid use disorder: a systematic review and meta-analysis.Addiction science & clinical practice · 2022Pooled it
- The association between physical activity and mental health during the first year of the COVID-19 pandemic: a systematic review.BMC public health · 2022Pooled it
- Alcohol and other substance use during the COVID-19 pandemic: A systematic review.Drug and alcohol dependence · 2021Pooled it
- Suicide during COVID-19 and other major international respiratory outbreaks: A systematic review.Asian journal of psychiatry · 2021Pooled it
- Substance use and mental health before versus during COVID-19 pandemic among persons who inject drugs with HCV infection history-the HERO study.Harm reduction journal · 2026Trial
- Impact of Social Drivers of Health, Self-Efficacy, and Substance Use on COVID-19 Preventative Behaviors Among Persons Who Inject Drugs with Hepatitis C: The HERO Study.International journal of environmental research and public health · 2026Article
- Differences in the Rates of Diagnoses of Mental and Behavioral Disorders Due to Psychoactive Substance Use by Sex and Age during Pre-Pandemic and COVID-19 Pandemic Periods in Kazakhstan.Healthcare (Basel, Switzerland) · 2024Article
- Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies.Harm reduction journal · 2024Article
- Challenges and Implications for Substance Use and Mental Healthcare Among Under-Resourced Women in the COVID-19 Era.Cureus · 2024Article
- Association of substance-use disorder with outcomes of major elective abdominal operations: A contemporary national analysis.Surgery open science · 2024Article
- Liver injury in COVID-19: an insight into pathobiology and roles of risk factors.Virology journal · 2024Review
- Predictors of COVID-19 vaccine uptake among people who use substances: a case study in Tehran.Substance abuse treatment, prevention, and policy · 2024Article
- Long-lasting blocking of interoceptive effects of cocaine by a highly efficient cocaine hydrolase in rats.Scientific reports · 2024Article
- Association between opioid abuse and COVID-19 susceptibility: a propensity score matched study.BMC infectious diseases · 2023Article
- Substances of abuse and their effect on SAR-CoV-2 pathogenesis.NeuroImmune pharmacology and therapeutics · 2023Review
- Identifying barriers and facilitators to COVID-19 vaccination uptake among People Who Use Drugs in Canada: a National Qualitative Study.Harm reduction journal · 2023Article
- COVID-19 Vaccine Uptake and Attitudes Within Two Cohorts of Younger Adult Cannabis Users.Journal of drug issues · 2023Article
- Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.The lancet. Psychiatry · 2023Article
- A qualitative study of people who use methamphetamine during the early COVID-19 pandemic to inform future ED harm reduction strategies.International journal of emergency medicine · 2023Article
- Experiences with Eviction, House Foreclosure, and Homelessness Among COVID-19 Infected Adults and Their Relation to Mental Health in a Large U.S. City.Journal of community health · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
As the world endures the coronavirus disease 2019 (COVID-19) pandemic, the conditions of 35 million vulnerable individuals struggling with substance use disorders (SUDs) worldwide have not received sufficient attention for their special health and medical needs. Many of these individuals are complicated by underlying health conditions, such as cardiovascular and lung diseases and undermined immune systems. During the pandemic, access to the healthcare systems and support groups is greatly diminished. Current research on COVID-19 has not addressed the unique challenges facing individuals with SUDs, including the heightened vulnerability and susceptibility to the disease. In this systematic review, we will discuss the pathogenesis and pathology of COVID-19, and highlight potential risk factors and complications to these individuals. We will also provide insights and considerations for COVID-19 treatment and prevention in patients with SUDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.